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Abstract  
The aim of this work is to develop new chitosan nanospheres for the delivery of 5-fluorouracil (5-
FU). Drug loaded nanospheres were prepared using a technique derived from a combination of 
coacervation and emulsion droplet coalescence methods. The size and morphology of nanospheres 
were characterized by laser light scattering and transmission electron microscopy. The 5-FU 
interaction with chitosan nanospheres was investigated by DSC analysis and FT-IR spectroscopy. 
The in vitro release was studied by dialysis bag technique. Cytotoxicity of 5-FU loaded chitosan 
nanospheres was evaluated in vitro on HT29 and PC-3 cell lines. The effects of 5-FU loaded 
chitosan nanospheres on adhesion of tumor cells to human umbilical vein endothelial cells 
(HUVEC) were also investigated. 5-FU loaded chitosan nanospheres appeared with a spherical 
shape, with a mean diameter of about 200 nm and a negative zeta potential of about - 6.0 mV. The 
successful interaction between drug and chitosan nanosphere matrix was demonstrated by both DSC 
and FT-IR analyses. The quantitative determination of 5-FU was assayed by UV-Vis analysis. The 
encapsulation efficiency of 5-FU content was about 70%. A kinetic study of in vitro release 
demonstrated that the percentages of 5-FU delivered from nanospheres was approx. 10% after 3 
hours. The in vitro studies showed that 5-FU loaded nanospheres were effective in reducing tumor 
cell proliferation in a time- and concentration-dependent manner. 5-FU nanospheres were also able 
to inhibit both HT29 and PC-3 adhesion to HUVEC after 48 hours of treatment. 
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Introduction 
The delivery of insufficient drug concentrations to the tumor site, after both intravenous and oral 
administration, and the high systemic toxicity of many anticancer drugs are the major reason for 
limited efficacy of chemotherapy. Nanomedicine, the medical application of nanotechnology, was 
proposed as a strategy to improve many current cancer treatments by allowing various advantages, 
such as the increase of water solubility, the site–specific accumulation and the sustained delivery of 
drugs [1]. In recent years, nanoparticles have been developed as drug carriers and they seems to be 
effective, providing low side effects and targeted action on cancer cells [2-5]. 
5- Fluorouracil (5-FU), or 5-fluoro-2,4-pyrimidindione, is one of the oldest chemotherapeutic 
agents and it has played a dominant role for decades in the treatment of breast cancer and of a 
variety of other solid tumors. 5-FU is an antimetabolite of the pyrimidine analog class which is 
widely used alone or in combination with chemotherapy regimens. It interferes with the synthesis of 
nucleic acid, inhibits DNA synthesis, and, eventually, inhibits cell growth [6]. As a consequence of 
a very rapid in vivo metabolism, 5-FU shows a short biological half-life [7]. Intravenous 
administration of 5-FU results in a large systemic distribution, with only a small fraction of the dose 
reaching the site of action. In addition, oral delivery is not a realistic option for delivering, because 
the drug displays a not uniform oral absorption. Moreover, tumor cells often undergo significant 
development of drug resistance. These problems lead to the need of high doses of 5-FU, so its use 
has been restricted by its systemic toxicities, as severe gastrointestinal toxicities, hematologic side 
effects and severe bone marrow disturbances [8].  
Various polymeric nanoparticles were proposed to improve the 5-FU administration [9-12]. 
Different polymers have been studied for 5-FU delivery, such as poly(glycolide-co-lactide-co-
caprolactone) nanoparticles [13], self-assembled thermo-sensitive polyelectrolyte complex 
nanoparticles [14] and bovin serum albumin (BSA) nanoparticles [15, 16]. Various liposomal 
formulations of 5-FU have been described [17]. Among polymeric nanoparticulate systems, 
chitosan is a polymer largely used for the 5-FU delivery, because of it can easily form nanoparticles 
by crosslinking with different agents, such as glutaraldheyde, sodium citrate, sodium hydroxide, 
formaldehyde [18, 22]. 
The aim of this work is to prepare small-sized polymeric nanospheres for the delivery of 5-FU. 
Chitosan was selected for nanospheres matrix, because of its biocompatibility,biodegradability and 
low toxicity [23, 24]. It is a linear cationic polysaccharide, composed of randomly distributed b-(1-
4) linked D-glucosamine and N-acetyl-D-glucosamine, derived from deacetylated chitin [25-
27].The positive charge of the chitosan macromolecule promotes the interaction with polyanions. It 
is worth noting that this process has been widely used to obtain drug carrier systems through 
complexation, forming nano-/microparticles specifically suitable for hydrophilic molecules [28-31]. 
The present work is focused on the improvement of the preparation process to obtain small chitosan 
nanospheres by the combination of coacervation and emulsion coalescence methods. 
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Material and Methods 
 
Materials 
 
5-Fluorouacil (5-FU), chitosan (medium molecular weight), Arlacel®83, Tween® 80 and sodium 
citrate monobasic were supplied from Sigma Aldrich. Fetal calf serum (FCS) (endotoxin tested) was 
obtained from Hyclone Laboratories (Logan, UT). Trypsin was provided by Difco Laboratories 
(Detroit, MI). M199 and RPMI-1640 (endotoxin tested), thiazolyl blue tetrazolium bromide were 
purchased from Sigma-Aldrich (St. Louis, MO). A chitosan aqueous solution (0.7% w/w) was 
obtained dissolving the polymer in a 0.1 M acetic acid solution. Milli Q water was used for all the 
experiments. All the other reagents were of analytical grade.The experiments were performed in 
triplicate. 
 
Preparation of 5-FU loaded chitosan nanospheres  
 
The nanosphere preparation method consists of a combination of coacervation and emulsion droplet 
coalescence methods [32, 33]. This method exploits an emulsion as template, in order to obtain 
nanosized particles, starting from nanosized emulsion droplets. For this purpose, an W/O emulsion, 
containing a chitosan aqueous solution at pH=5.0 with 5-FU (10 mg/ml) as internal phase, was 
prepared. Arlacel 83 and Tween 80 were selected as surfactants and mineral oil as external phase. 
The quali-quantiative composition of the W/O emulsion is reported in the Table 1. The emulsion 
was obtained after homogenization for 3 minutes using an high shear homogenizer (Ultraturrax, 
IKA, Germany) and sonication for 10 minutes in order to reduce drop sizes. Then the W/O system 
was dropped by a syringe, using a roller pump into a sodium citrate aqueous solution (0,1 M) under 
magnetic stirring (Fig.1). This semi-automatic technique was tailored to guarantee a high 
reproducibility to the preparation process, avoiding manual mistakes. Completed the drift phase, the 
nanosphere dispersion was left under stirring for 30 minutes; then, after further 60 minutes, it was 
centrifuged to remove mineral oil derived from the W/O emulsion and then it was washed. Finally, 
the aqueous suspension of nanospheres was filtered through a filter paper. The nanosphere aqueous 
dispesion was stored at 4°C. Blank nanospheres were obtained using the same preparation method 
in the absence of 5-FU. 
Samples of the two nanosphere aqueous dispersions were freeze-dried using a Modulyo freeze-drier 
(Edwards, UK) to obtain a dry product. 
 
Table 1 W/O Emulsion quali-quantitative composition. 
 Component Amount (%) 
Oily phase 
 
 
Mineral oil 46.15 
Arlacel 83 3.50 
Tween
®
 80 0.35 
Aqueous phase Chitosan aqueous solution (pH 5.0) 50.00 
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Figure 1  Schematic representation of the experimental set-up for chitosan nanosphere preparation 
 
 
Characterization of 5-FU loaded chitosan nanospheres 
 
- Determination of particle size and Zeta potential 
Mean particle diameter, polydispersity index and Zeta potential of the 5-FU loaded nanospheres 
and blank nanospheres were determined by Photon Correlation Spectroscopy using a 90 Plus 
Instrument Brookhaven, at a fixed scattering angle of 90°, at room temperature. The nanosphere 
dispersion was diluted with filter water and analyzed in triplicate. 
 
 
- Evaluation of nanosphere morphology  
The morphology and size of 5-FU loaded nanospheres were observed by Transmission Electron 
Microscopy (TEM) (CM10, Philips). A drop of the 5-FU loaded nanosphere aqueous dispersion 
was diluted with filtered water and placed onto a copper micro-grid and evaporated in air at 
room temperature before observation.  
 
- Differential scanning calorimetry 
Differential scanning calorimetry (DSC) analysis was carry out using a DSC7 Perkin Elmer 
instrument, connected to a computer with Pyris Software Version 3.7.1. The instrument was 
calibrated with indium for melting point and heat of fusion. DSC thermograms of blank 
nanoparticles, free 5-FU, 5-FU-loaded nanoparticles were evaluated. 
A weighed amount of 3-4 mg of freeze-dried chitosan nanospheres containing 5-FU and of 1.5-2 
mg free 5-FU were put in suitable aluminum pans. The analysis was performed in the 
temperature range between 25°C and 300°C, at a speed of 10 °C per minute under a nitrogen 
flow. 
 
- Fourier transformed infra-red (FT-IR) spectroscopy 
Fourier transform infra-red spectroscopy (FTIR) was applied to 5-FU loaded chitosan 
nanospheres, blank chitosan nanospheres and free 5-FU using a Perkin Elmer system 2000 
spectrophotometer. The spectra were recorded between 4000–400 cm−1 using KBr pellets. 
 
 
Determination of 5-FU encapsulation efficiency in the nanospheres  
 
The quantative determination of 5-FU content in the nanospheres was assayed by UV-Vis analysis 
with a Beckman-Coulter DU 730 spectrophotometer. 5-FU concentrations were obtained by 
reference to a calibration curve. The calibration curve is linear in the range 2–15 μg/ml with a r2 of 
0.9996. The wavelenght selected for determination of 5-FU concentration was 266 nm. The 
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encapsulation efficiency and loading capacity of 5-FU-loaded chitosan nanospheres were evaluated 
by separation of nanospheres from aqueous medium containing non-associated 5-FU by 
ultracentrifugation at 8000 rpm for 30 minutes at 25°C. The amount of free 5-FU in the supernatant 
were diluted with water and analyzed spectrophotometically. 
 
In vitro drug release studies 
 
The in vitro release of 5-FU from the chitosan nanospheres was investigated in phosphate buffer 
solution at pH 7.4.  
The in vitro release studies were carried out using multicompartment rotating cells with a 
hydrophilic dialysis membrane (Spectra/Por, Spectrum®, cut-off 12000-14000 Da). For this purpose, 
a phosphate buffer suspension of 5-FU-loaded nanospheres (drug concentration: 1 mg/ml) was 
compared to free 5-FU (1 mg/ml) also dissolved in phosphate buffer (pH = 7.4). The experiment 
was conducted for 5 hours and the receiving phase, which consisted of phosphate buffer pH 7.4, 
was completely withdrawn and replaced with fresh medium after fixed time intervals. The amount 
of drug released was measured spectrophotometrically at 266 nm. The experiment was carried out 
in triplicate. 
 
 
Cell and culture conditions 
 
HT29 cells were derived from human colon adenocarcinoma and PC-3 cells were derived from 
human prostate carcinoma. Both of them were obtained from the American Type Culture Collection 
(ATCC; Manassas, VA, USA). They were cultured at 37 °C in a 5% CO2 humidified atmosphere in 
RPMI 1640 medium supplemented with 10% FCS, 100 U/ml penicillin and 100 μg/ml 
streptomycin.  
 
Cell proliferation 
 
MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5diphenyltetrazolium bromide) analysis was performed in 96-
well plates. 1000 cells/well were seeded in 100 μl of complete medium. After 24 hours, they were 
treated for 48-72 hours with increasing concentration of 5-FU or nanospheres of 5-FU (10
-6
-10
-5
M). 
Subsequently, cells were supplemented with 11 μl of 5 mg/ml thiazolyl blue tetrazolium bromide 
for 2 hours. Thereafter, the medium was removed and cells were lysed with 100 μl of DMSO. 
Absorbance was recorded at 570 nm by a 96-well-plate ELISA reader.  
 
Fluorescent labeling of HT29 and PC-3 cells 
 
Commercial fluorescent cell linker kit PKH67 was used for membrane labeling of HT29 and PC-3 
cells, following the manufacturer’s directions as described in the kit. The staining efficiency was 
monitored by fluorescent microscopy. 
 
 
  
 
6 
 
Cell adhesion assay 
 
HUVECs (Human Umbilical Vein Endothelial Cells) were isolated from human umbilical veins by 
trypsin treatment (1%). They were cultured in M199 medium, with the addition of 20% FCS, 100 
U/ml penicillin, 100 mg/ml streptomycin, 5 UI/ml heparin, 12 mg/ml bovine brain extract, and 200 
mM glutamine. HUVECs were grown up to confluence in flasks and they were used at passages 
two through five. The use of HUVEC was approved by the Ethics Committee of the ‘‘Presidio 
Ospedaliero Martini’’ of Turin (Italy) and conducted in accordance with the Declaration of Helsinki. 
Written informed consent was obtained from all donors. 
HUVECs were grown up to confluence in 24-well plates, washed, and rested for one day in M199 
plus 10% FCS. For titration experiments, HUVECs were treated or not  for 24-48 hours with 
increasing concentrations of 5-FU or with 5-FU loaded chitosan nanospheres (10
-7
-10
-5
M). After the 
treatments, HUVECs were incubated for one hour with prelabeled tumor cell line (1x10
5
 cell/well). 
One hour incubation time was chosen in order to allow a full sedimentation of the adhering cells 
[34]. After incubation, non-adherent cells were removed by washing three times with M199. The 
center of each cell was analyzed by fluorescence image analysis. Adherent cells were counted using 
Image Pro Plus Software for microimaging (version 5.0; Media Cybernetics, Bethesda, MD). Single 
experimental points were assayed in triplicate, and the SEM of the three replicates was always close 
to 10%. Data are shown as percentage of inhibition versus the control adhesion measured on 
HUVECs not treated with the drug. This control adhesion was 65±4 cells/microscope field (n = 5) 
for HT29 cells and in a similar range for PC-3.  
 
Statistical analysis 
 
Data are expressed as means±SEM of n=5 experiments. Statistical analysis was performed with 
GraphPad Prism 4.0 software. Significance was assessed with Student’s t-test for paired varieties or 
one-way ANOVA and the Dunnett test with p≤ 0.05 as the cut-off. 
 
 
Results and discussion 
 
In this work, the developed preparation technique consists of a combination of coacervation and 
emulsion droplet coalescence methods. The coacervation exploits the physico-chemical property of 
chitosan, insoluble at alkaline pH, to precipitate when it comes in contact with basic solutions. 
Nevertheless, this method is not suitable to obtain systems in the nanometric range and with a high 
drug loading. Generally, chitosan nanoparticles were obtained using the ionic gelation of the 
polymer with sodium tripolyphosphate (TPP) solutions [35]; nanoparticles formed through the 
intermolecular cross-linking of amino groups of chitosan with the negative phosphate groups of 
TPP. Tuning the molecular weight, degree of deacetylation and the concentration of chitosan, it is 
possible to prepare small nanoparticles, with uniform nanoparticles [36]. Alternatively, a complex 
coacervation can be used to prepare chitosan nanoparticles, consisting of the addition to a chitosan 
solution an oppositely charged polyelectrolyte solution. 
The emulsion-droplet coalescence method uses the principles of both emulsion cross-linking, based 
on the linking between chitosan and different cross-linking agents, and precipitation in a base 
solution. In this protocol, a stable water-in-oil emulsion of chitosan solution and a similar one 
containing a NaOH solution were prepared. Mixing both the emulsions, a precipitation is induced 
due to the coalescence of chitosan droplets with NaOH droplets [37].  
The preparation method developed in this work exploits an emulsion as template, in order to obtain 
nanosized particles, starting from nanosized emulsion droplets. Recently, template methods have 
been proposed to obtain nanoparticles with a monodisperse size distribution [38]. We developed a 
semi-automatic technique, based on the use of a roller pump to drop the emulsion at constant rate 
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through a syringe needle, to ensure a high reproducibility of the preparation process avoiding 
manual mistakes. Moreover, this experimental set-up is ease for scaling-up. It is worth noting that 
no toxic solvents were used to obtain the emulsion and all the components are admitted for 
pharmaceutical use. 
 
Average diameter, polydispersity, and zeta potential of prepared blank chitosan nanospheres and 5-
FU loaded chitosan nanospheres  were about 210 nm, 0.17, and -8.2 mV and about 199 nm, 0.10 
and - 6.5 mV, respectively. (Table 2).  
 
Table 2  Characteristic of blank chitosan nanospheres and 5-FU loaded chitosan nanospheres. 
 Average diameter 
(nm) 
Polydispersity index Zeta Potential (mV) 
Blank Chitosan Nanospheres 209.5 ± 24.0 0.17 ± 0.02 -8.2 ± 0.3 
5-FU loaded Chitosan Nanospheres 198.6 ± 14.3 0.10 ± 0.04 -6.5 ± 0.8 
 
For cancer therapy, the average size and size distribution of nanoparticles are critical determinants 
for  their bioavailability [39]. In fact, particles with an average size lower than 500 nm can mainly 
extravasate and accumulate in tumor parenchyma, though a passive mechanism, exploiting the 
enhanced permeation and retention effect (EPR). 
A representative TEM micrograph of the 5-FU loaded nanospheres showed that nanoparticles have 
a spherical shape and smooth surface. TEM analysis also reveals that 5-FU-loaded chitosan 
nanospheres are discrete and non-aggregated (Fig.2a), as confirmed by the particle size analysis 
(Fig. 2 b) 
 
         
 
Figure 2 a) TEM micrograph b) Size distribution graph of 5-FU loaded nanospheres 
 
The 5-FU interaction with chitosan nanospheres was confirmed by DSC analysis. The DSC 
thermograms of 5-FU-loaded nanospheres, blank nanospheres and free 5-FU are showed in Fig.3. 
The drug shows an endothermic peak at about 280°C, in correspondence to the 5-FU fusion. This 
peak is not present in the DSC thermograms of both 5-FU-loaded nanospheres. This disappearance 
of the drug melting peak indicates that 5-FU is molecularly dispersed in the chitosan matrix, which 
composes nanospheres, and it is not able to crystallize, confirming the 5-FU interaction with the 
nanosphere structure.  
 
200 nm 
  
 
8 
 
 
Figure 3  DSC thermograms of free 5-FU, 5-FU-loaded nanospheres and blank nanospheres. 
 
 
 
FTIR spectra of 5-FU loaded chitosan nanospheres, blank chitosan nanospheres and free 5-
FU are shown in Fig.4. In the free 5-FU spectrum the specific peaks of the drug molecule 
are visible, such as the peak of the carbon-fluorine bond between 1400-1200 cm
-1
. The 
spectrum of chitosan shows an enlarged band between 3500-3000 cm
-1
, where hydroxyl 
groups and amino groups stretching overlap. Bands relative to CO and COC groups, both 
very frequent in the molecule of chitosan, are also clearly visible between 1200-1000 cm
-1
. 
The successful interaction between drug and nanospheres is demonstrated in the spectrum of 
the 5-FU loaded nanospheres from the displacement and the peak change of the typical 
bands of the drug. 
 
 
Figure 4  FTIR spectra of free 5-FU, 5-FU loaded chitosan nanospheres and blank chitosan 
nanospheres  
 
 
In order to determine the 5-FU content in the nanospheres UV-visible spectrophotometric analysis 
was carried out. The mean of encapsulation efficiency percentages with the standard deviation of 5-
FU content was 69.9 ± 3.9 and the loaded capacity was about 42%. It is  supposed that the drug loss 
may be caused by the purification processes, aimed to eliminate the oily phase. The drug loading 
did not change over time. 
The advantages of nanoparticles for the delivery of anticancer agents can include: prolonged drug 
release, enhanced drug accumulation in cancer tissues, prolonged  half-life in blood circulation and 
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increased cellular trafficking of the drug incorporated in their structure [40]. In this work the release 
profile of 5FU from nanospheres showed much slowly compared to the free drug. The results of the 
in vitro release kinetics study of 5-FU from the chitosan nanospheres in comparison with free 5-FU 
are shown in Fig. 5. 
5-FU-loaded  nanospheres did not show an initial burst effect, proving that the active molecule was 
incorporated into the chitosan matrix of nanospheres and not adsorbed on their surface. After 3 
hours the amount of 5-FU released from nanospheres was approx 10%. The constant and slow 
release profile of the drug might be related to the slow diffusion of 5-FU within the cross-linked 
polymer matrix. A sustained and low release of 5-FU can prevent the non-specific toxicity of 5-FU 
decreasing the amount of free drug and related side effects, as previously reported [41].  
 
 
 
 
 
 
 
 
Figure 5 Percentage of 5-FU released from chitosan nanospheres in comparison with free 5-FU over 
time. Each point represents the mean (n = 3). 
 
 
The anti-tumor efficacy of 5-FU loaded chitosan nanospheres, blank chitosan nanospheres and free 
5-FU was carried out on HT29 cells, derived from human colon adenocarcinoma, are reported in 
Figs. 6a and 6b, respectively. HT29 cells were treated for 48-72 hours with increasing concentration 
of the drugs (10
-6
-10
-5
M). The results show that both formulations were effective in reducing cell 
proliferation in a time- and concentration-dependent manner. After 48 and 72 hours of treatment, 5-
FU decreased HT29 growth and 5-FU loaded chitosan nanospheres showed a statistically greater 
efficacy. In order to confirm the higher anti-tumor efficacy of the 5-FU loaded chitosan 
nanospheres, experiments were repeated with PC-3, a different cancer cell lines, derived from 
human prostate carcinoma. The inhibition effect of 5-FU was lower on these cells, being active only 
after 72 hours of incubation (Fig.6c and 6d). Nevertheless, the 5-FU nanospheres inhibited PC-3 
proliferation to a similar extent, and with a similar kinetics to that displayed on HT29. By contrast, 
blank chitosan nanospheres were completely ineffective in all the experiments (data not shown), as 
previously reported for different chitosan formulation[42].The nanosphere formulation may 
increase the amount of 5-FU entering the two cell lines. Indeed fluorescent chitosan nanopheres can 
be internalized by cancer cells (data not shown). 
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Figure 6 Inhibition of proliferation following 5-FU and 5-FU loaded chitosan nanospheres treatment. HT29 (a,b) 
and PC-3 (c,d) (1000 cells per well) were treated with increasing concentrations (10
-6
-10
-5
M) of 5-FU and 5-FU loaded 
chitosan nanospheres for 48 (a,c) – 72 (b,d) hours. Results are expressed as % inhibition of control and shown as mean 
± SEM (n = 5). *P < 0.05; **P < 0.01, significantly different from control; ǂ P < 0.05 significantly different from 5-FU; 
one-way ANOVA and Dunnett’s test. 
 
To assess the effect of 5-FU and 5-FU loaded chitosan nanospheres on tumor cells adhesion to ECs, 
HUVECs were treated or not with different concentrations of the two formulation (10
-7
-10
-5
M) for 
24-48 hours. After that, they were used in the adhesion assay with each tumor cell line. Fig. 7 (a= 
HT29; b= PC-3) shows that both formulations were effective in reducing tumor cell adhesion. 
However, a significant difference was revealed after 24 hours of treatment, being the 5-FU loaded 
chitosan nanospheres more effective at the highest concentration tested. Maximal inhibitions were 
58 ± 5% for 10
-5
M 5-FU loaded chitosan nanospheres and only 33 ± 2% for 10
-5
M 5-FU. It is worth 
noting that only the 5-FU loaded chitosan nanospheres were able to inhibit HT29 adhesion to 
HUVEC after 48 hours of treatment. 
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Figure 7  Effect of HUVEC treatment with 5-FU and 5-FU loaded chitosan nanospheres on HT29 cell line adhesion. 
HUVECs were pretreated or not with increasing concentrations (10
-7
-10
-5
M) of 5-FU and 5-FU loaded chitosan 
nanospheres for 24 (a) - 48 (b) hours and then incubated with HT29 cell line for 1 hour. Results are expressed as % 
inhibition of control and shown as mean ± SEM (n = 5). *P < 0.05; **P < 0.01, significantly different from control; ǂ P 
< 0.05; ǂǂ P < 0.01 significantly different from 5-FU; one-way ANOVA and Dunnett’s test. 
 
Fig. 8 shows micrographs of the HT29 adhesion assays on untreated HUVECs (panel a) or those 
that were treated with 10
-5
M of 5-FU (panel b) or 5-FU loaded chitosan nanospheres (panel c). It is 
worth noting that only the 5-FU loaded chitosan nanospheres were able to inhibit HT29 adhesion to 
HUVEC after 48 hours of treatment.  
 
Figure 82  Fluorescent microscopy of HT29 cells adherent to HUVECs. HUVECs were not treated (panel a), or 
treated with 5-FU (panel b), and 5-FU loaded chitosan nanospheres (panel c) (x100 magnification). 
The adhesion experimental test was repeated using the PC-3 cell line. The results were similar to 
those obtained with HT29 cell line (Fig.9).  
 
 
 
Figure 9 Effect of HUVEC treatment with 5-FU and 5-FU loaded chitosan nanospheres on PC-3 cell line adhesion. 
HUVECs were pretreated or not with increasing concentrations (10
-7
-10
-5
M) of 5-FU and 5-FU loaded chitosan 
nanospheres for 24 (a) - 48 (b) hours and then incubated with PC-3 cell line for 1 hour. Results are expressed as % 
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inhibition of control and shown as mean ± SEM (n = 5). *P < 0.05; **P < 0.01, significantly different from control; ǂ P 
< 0.05; ǂǂ P < 0.01 significantly different from 5-FU; one-way ANOVA and Dunnett’s test. 
 
Conclusion 
5-FU loaded chitosan nanospheres of about 200 nm sized were obtained using a purposely tuned set 
up, ease to be scaled. They showed a good encapsulation efficiency and prolonged release profile of 
the drug. The incorporation of the 5-FU in the nanocarrier may be exploited to improve the 
therapeutic effect and to overcome the drug resistance. 
Development of resistance by cancer cells to chemotherapeutic agents has currently become a major 
clinical problem, limiting the effectiveness of the treatment of hematological malignancies as well 
as solid tumors. One mechanism of drug resistance is due to the prevention of a drug from entering 
cells; this can depend from deficiencies in membrane nucleoside transporters or the overexpression 
of ATP-dependent drug efflux transporters like P-glycoprotein. Therefore, the drug accumulation is 
substantially reduced when the expression of such nucleoside transporters is deficient or the activity 
of drug efflux transporter proteins elevated. We suggest that 5-FU loaded chitosan nanospheres may 
overcome these transport defects by entering into the cells without a specific carrier-mediated 
transport. This mechanism is under investigation and it will be described in a future work. 
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